tradingkey.logo

Evolus Inc

EOLS
6.900USD
+0.050+0.73%
收盘 12/26, 16:00美东报价延迟15分钟
446.89M总市值
亏损市盈率 TTM

Evolus Inc

6.900
+0.050+0.73%

关于 Evolus Inc 公司

Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.

Evolus Inc简介

公司代码EOLS
公司名称Evolus Inc
上市日期Feb 08, 2018
CEOMoatazedi (David)
员工数量332
证券类型Ordinary Share
年结日Feb 08
公司地址520 Newport Center Dr Ste 1200
城市NEWPORT BEACH
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编92660-7022
电话19492844555
网址https://www.evolus.com/
公司代码EOLS
上市日期Feb 08, 2018
CEOMoatazedi (David)

Evolus Inc公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Vikram Malik
Mr. Vikram Malik
Independent Chairman of the Board
Independent Chairman of the Board
265.91K
+9.47%
Ms. Tatjana Mitchell
Ms. Tatjana Mitchell
Chief Financial Officer
Chief Financial Officer
104.60K
--
Mrs. Brady Stewart
Mrs. Brady Stewart
Independent Director
Independent Director
81.27K
+58.52%
Mr. David N. Gill
Mr. David N. Gill
Independent Director
Independent Director
33.96K
-14.80%
Ms. Karah Parschauer, J.D.
Ms. Karah Parschauer, J.D.
Independent Director
Independent Director
--
--
Mr. Albert G. White, III
Mr. Albert G. White, III
Independent Director
Independent Director
--
--
Mr. Nareg Sagherian
Mr. Nareg Sagherian
Investor Relations
Investor Relations
--
--
Dr. Rui L. Avelar, M.D.
Dr. Rui L. Avelar, M.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
--
--
Mr. David Moatazedi
Mr. David Moatazedi
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
-100.00%
名称
名称/职务
职务
持股
持股变动
Mr. Vikram Malik
Mr. Vikram Malik
Independent Chairman of the Board
Independent Chairman of the Board
265.91K
+9.47%
Ms. Tatjana Mitchell
Ms. Tatjana Mitchell
Chief Financial Officer
Chief Financial Officer
104.60K
--
Mrs. Brady Stewart
Mrs. Brady Stewart
Independent Director
Independent Director
81.27K
+58.52%
Mr. David N. Gill
Mr. David N. Gill
Independent Director
Independent Director
33.96K
-14.80%
Ms. Karah Parschauer, J.D.
Ms. Karah Parschauer, J.D.
Independent Director
Independent Director
--
--
Mr. Albert G. White, III
Mr. Albert G. White, III
Independent Director
Independent Director
--
--

收入明细

由于公司未披露,未能获取相关数据
由于公司未披露,未能获取相关数据
业务
地区
由于公司未披露,未能获取相关数据

股东统计

更新时间: 11月16日 周日
更新时间: 11月16日 周日
持股股东
股东类型
持股股东
持股股东
占比
Nantahala Capital Management, LLC
8.84%
Tang Capital Management, LLC
8.47%
Lynch (Timothy Patrick)
7.92%
Caligan Partners, LP
6.39%
BlackRock Institutional Trust Company, N.A.
6.15%
其他
62.24%
持股股东
持股股东
占比
Nantahala Capital Management, LLC
8.84%
Tang Capital Management, LLC
8.47%
Lynch (Timothy Patrick)
7.92%
Caligan Partners, LP
6.39%
BlackRock Institutional Trust Company, N.A.
6.15%
其他
62.24%
股东类型
持股股东
占比
Hedge Fund
38.96%
Investment Advisor
22.15%
Investment Advisor/Hedge Fund
15.60%
Individual Investor
10.06%
Private Equity
4.06%
Corporation
3.30%
Research Firm
2.38%
Pension Fund
0.47%
Bank and Trust
0.30%
其他
2.73%

机构持股

更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
356
58.38M
89.22%
--
2025Q3
366
58.59M
90.20%
-409.50K
2025Q2
368
58.97M
91.09%
+3.93M
2025Q1
354
55.05M
88.70%
-1.35M
2024Q4
343
52.59M
87.55%
+1.63M
2024Q3
334
50.95M
89.20%
-1.08M
2024Q2
328
52.17M
86.99%
+2.08M
2024Q1
314
50.10M
82.52%
-553.42K
2023Q4
296
45.99M
83.45%
+2.48M
2023Q3
294
41.91M
82.26%
+3.40M
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
Nantahala Capital Management, LLC
4.20M
6.49%
+546.58K
+14.97%
Jun 30, 2025
Tang Capital Management, LLC
5.00M
7.73%
--
--
Jun 30, 2025
Lynch (Timothy Patrick)
4.09M
6.33%
+4.09M
--
Aug 11, 2025
Caligan Partners, LP
3.34M
5.17%
+610.82K
+22.36%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.65M
5.64%
-175.30K
-4.58%
Jun 30, 2025
The Vanguard Group, Inc.
3.31M
5.11%
+84.18K
+2.61%
Jun 30, 2025
Frazier Life Sciences Management, L.P.
2.44M
3.77%
+2.44M
--
Jun 30, 2025
Medy Tox Inc
2.14M
3.3%
-1.24M
-36.82%
Dec 31, 2024
Millennium Management LLC
1.48M
2.29%
+91.40K
+6.57%
Jun 30, 2025
查看更多

持股ETF

更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
State Street SPDR S&P Pharmaceuticals ETF
0.97%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.93%
iShares U.S. Pharmaceuticals ETF
0.15%
iShares Micro-Cap ETF
0.07%
ProShares Ultra Nasdaq Biotechnology
0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.06%
Invesco Nasdaq Biotechnology ETF
0.04%
ProShares Hedge Replication ETF
0.02%
iShares Russell 2000 Growth ETF
0.02%
Schwab U.S. Small-Cap ETF
0.01%
查看更多
State Street SPDR S&P Pharmaceuticals ETF
占比0.97%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
占比0.93%
iShares U.S. Pharmaceuticals ETF
占比0.15%
iShares Micro-Cap ETF
占比0.07%
ProShares Ultra Nasdaq Biotechnology
占比0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
占比0.06%
Invesco Nasdaq Biotechnology ETF
占比0.04%
ProShares Hedge Replication ETF
占比0.02%
iShares Russell 2000 Growth ETF
占比0.02%
Schwab U.S. Small-Cap ETF
占比0.01%

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据

常见问题

Evolus Inc的前五大股东是谁?

Evolus Inc 的前五大股东如下:
Nantahala Capital Management, LLC持有股份:4.20M,占总股份比例:6.49%。
Tang Capital Management, LLC持有股份:5.00M,占总股份比例:7.73%。
Lynch (Timothy Patrick)持有股份:4.09M,占总股份比例:6.33%。
Caligan Partners, LP持有股份:3.34M,占总股份比例:5.17%。
BlackRock Institutional Trust Company, N.A.持有股份:3.65M,占总股份比例:5.64%。

Evolus Inc的前三大股东类型是什么?

Evolus Inc 的前三大股东类型分别是:
Nantahala Capital Management, LLC
Tang Capital Management, LLC
Lynch (Timothy Patrick)

有多少机构持有Evolus Inc(EOLS)的股份?

截至2025Q4,共有356家机构持有Evolus Inc的股份,合计持有的股份价值约为58.38M,占公司总股份的89.22%。与2025Q3相比,机构持股有所增加,增幅为-0.98%。

哪个业务部门对Evolus Inc的收入贡献最大?

在--,--业务部门对Evolus Inc的收入贡献最大,创收--,占总收入的--%。
KeyAI